HomeIndustriesBanks & FinanceCytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO On Future Of Heart Disease Treatment

Cytokinetics (CYTK) CEO Robert Blum joins Nicole Petallides to give an overview of the company and discusses its Aficamten trial. He talks about how the Sequoia-HCM Phase 3 clinical trial showed the best-case scenario result for obstructive hypertrophic cardiomyopathy. He goes over the future of heart disease treatment. Cytokinetics is a biopharma company with a focus on muscle activators and inhibitors as potential disease treatments. Tune in to find out more about the stock market today.

Trading 360

03 Jan 2024

SHARE

ON AIR
education
12:00 am
Your First Trade
replay
ON AIR
education
12:00 am
Your First Trade
REPLAY
education
12:30 am
Your First Trade
REPLAY
1:00 am
The Wrap
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Market Overtime
REPLAY
4:00 am
Market Overtime
REPLAY
education
4:30 am
Inside the Mind of a Trader
REPLAY
education
5:00 am
Inside the Mind of a Trader
REPLAY
education
5:30 am
Inside the Mind of a Trader
REPLAY
6:00 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
7:00 pm
Market Overtime
REPLAY
7:30 pm
Market Overtime
REPLAY
8:00 pm
The Wrap
REPLAY
9:00 pm
Market Overtime
REPLAY
9:30 pm
Market Overtime
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Next Gen Investing
REPLAY

Schwab Network's Newsletters

Daily insights for every investor